Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 196 of the 206 references it cites were found in a registry or an index.

Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis

Abstract

Introduction: Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease, with type 2 diabetes mellitus (T2DM) as a major predictor. Insulin resistance and chronic inflammation are key pathways in the pathogenesis of T2DM leading to NAFLD and vice versa, with the synergistic effect of NAFLD and T2DM increasing morbidity and mortality risks. This meta-analysis aims to quantify the prevalence of NAFLD and the prevalence of clinically significant and advanced fibrosis in people with T2DM. Methods: MEDLINE and Embase databases were searched from inception until 13 February 2023. The primary outcomes were the prevalence of NAFLD, non-alcoholic steatohepatitis (NASH) and fibrosis in people with T2DM. A generalised linear mixed model with Clopper-Pearson intervals was used for the analysis of proportions with sensitivity analysis conducted to explore heterogeneity between studies. Results: 156 studies met the inclusion criteria, and a pooled analysis of 1 832 125 patients determined that the prevalence rates of NAFLD and NASH in T2DM were 65.04% (95% CI 61.79% to 68.15%, I 2 =99.90%) and 31.55% (95% CI 17.12% to 50.70%, I 2 =97.70%), respectively. 35.54% (95% CI 19.56% to 55.56%, I 2 =100.00%) of individuals with T2DM with NAFLD had clinically significant fibrosis (F2–F4), while 14.95% (95% CI 11.03% to 19.95%, I 2 =99.00%) had advanced fibrosis (F3–F4). Conclusion: This study determined a high prevalence of NAFLD, NASH and fibrosis in people with T2DM. Increased efforts are required to prevent T2DM to combat the rising burden of NAFLD. PROSPERO registration number: CRD42022360251.

Overview

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2023-330110

Cites

196 of 196 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 206 references

Research works printed but not linked: 4

  1. Huang DQ , Wilson LA , Behling C , et al . Fibrosis progression rate in biopsy-proven Nonalcoholic fatty liver disease among people with diabetes versus people without diabetes: A multicenter study. Gastroenterology 2023. doi:10.1053/j.gastro.2023.04.025 · DOI · Paper page
  2. 2015, Standards of medical care in Diabetes--2015: summary of revisions, Diabetes Care, 38 Suppl
  3. Muthiah, 2023, Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis, Ann Hepatol, 28, 100762, 10.1016/j.aohep.2022.100762 · DOI
  4. Ajmera V , Cepin S , Tesfai K , et al . 2023 A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. Journal of Hepatology:471–8. doi:10.1016/j.jhep.2022.11.010 Available: doi:https://doi.org/10.1016/j.jhep.2022.11.010 · DOI · Paper page

Cited by

See all 382

Metadata

Authors
En Li Cho, E., Ang, C. Z., Quek, J., Fu, C. E., Lim, L. K. E., Heng, Z. E. Q., Tan, D. J. H., Lim, W. H., Yong, J. N., Zeng, R., Chee, D., Nah, B., Lesmana, C. R. A., Bwa, A. H., Win, K. M., Faulkner, C., Aboona, M. B., Lim, M. C., Syn, N., Kulkarni, A. V., Suzuki, H., Takahashi, H., Tamaki, N., Wijarnpreecha, K., Huang, D. Q., Muthiah, M., Ng, C. H., & Loomba, R.
Affiliations
  • Department of Medicine, National University Hospital, Singapore
  • National University Hospital (SG)
  • National University of Singapore (SG)
  • University of Indonesia (ID)
  • Department of Medical Research, Union of Myanmar, Naypyidaw, Myanmar
  • University of Arizona College of Medicine- Phoenix (US)
  • Asian Institute of Gastroenterology (IN)
  • Kurume University (JP)
  • Saga University (JP)
  • University of California San Diego (US)
  • University of Michigan (US)
Corresponding author
Ng, Cheng Han
Venue
Gut
Publisher
BMJ
Published
2023-07-25
Volume
72
Issue
11
Pages
2138-2148
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W4385237448
Cited by
380
References
206
Citations by year
2026: 135 · 2025: 154 · 2024: 79 · 2023: 12
FWCI
14.79
Type
journal article
Language
en
Open access
closed
Locations
  • Gut (publishedVersion)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Keywords
non-alcoholic fatty liver disease, type 2 diabetes, prevalence, nonalcoholic steatohepatitis, liver fibrosis, advanced fibrosis, insulin resistance, chronic inflammation
MeSH terms
Diabetes Mellitus, Type 2, Fibrosis, Humans, Insulin Resistance, Prevalence, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. https://app.cochat.ai/papers/10.1136/gutjnl-2023-330110
The paper
En Li Cho, E., Ang, C. Z., Quek, J., Fu, C. E., Lim, L. K. E., Heng, Z. E. Q., Tan, D. J. H., Lim, W. H., Yong, J. N., Zeng, R., Chee, D., Nah, B., Lesmana, C. R. A., Bwa, A. H., Win, K. M., Faulkner, C., Aboona, M. B., Lim, M. C., Syn, N., . . . Loomba, R. (2023). Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. Gut. https://doi.org/10.1136/gutjnl-2023-330110

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.